These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34684144)

  • 1. Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease.
    Pizzolato K; Thacker D; Toro-Pagán ND; Hanna A; Turgeon J; Matos A; Amin N; Michaud V
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of Cannabis on hallucinations in Parkinson's disease patients.
    Cravanas B; Frei K
    J Neurol Sci; 2020 Dec; 419():117206. PubMed ID: 33161300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.
    Redenšek S; Jenko Bizjan B; Trošt M; Dolžan V
    Int J Neuropsychopharmacol; 2020 Nov; 23(8):496-504. PubMed ID: 32710539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early dopaminergic drug-induced hallucinations in parkinsonian patients.
    Goetz CG; Vogel C; Tanner CM; Stebbins GT
    Neurology; 1998 Sep; 51(3):811-4. PubMed ID: 9748031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease.
    Damasceno Dos Santos EU; Duarte EBC; Miranda LMR; Asano AGC; Asano NMJ; Maia MMD; de Souza PRE
    J Clin Pharmacol; 2019 Jul; 59(7):1006-1013. PubMed ID: 30794329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease.
    Papapetropoulos S
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):149-57. PubMed ID: 16720791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines.
    Kuepper R; Morrison PD; van Os J; Murray RM; Kenis G; Henquet C
    Schizophr Res; 2010 Aug; 121(1-3):107-17. PubMed ID: 20580531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?
    Kataoka H; Sawa N; Sugie K; Ueno S
    J Neurol Sci; 2014 Dec; 347(1-2):361-3. PubMed ID: 25454646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual Hallucinations and the Role of Medications in Parkinson's Disease: Triggers, Pathophysiology, and Management.
    Powell A; Ireland C; Lewis SJG
    J Neuropsychiatry Clin Neurosci; 2020; 32(4):334-343. PubMed ID: 32374649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
    Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
    No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.
    D'Souza DC; Ranganathan M; Braley G; Gueorguieva R; Zimolo Z; Cooper T; Perry E; Krystal J
    Neuropsychopharmacology; 2008 Sep; 33(10):2505-16. PubMed ID: 18185500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
    Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
    Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of hallucinations induced by long-term drug therapy.
    Goetz CG; Tanner CM; Klawans HL
    Am J Psychiatry; 1982 Apr; 139(4):494-7. PubMed ID: 6802003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tactile hallucinations induced by trihexyphenidyl in a patient with Parkinson's disease].
    Funakawa I; Jinnai K
    Rinsho Shinkeigaku; 2005 Feb; 45(2):125-7. PubMed ID: 15782612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson's patients.
    Ferrari M; Comi C; Marino F; Magistrelli L; De Marchi F; Cantello R; Riboldazzi G; Bono G; Cosentino M
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1335-1341. PubMed ID: 27497990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual hallucinations in photographs in Parkinson's disease.
    Vaou O; Saint-Hilaire M; Friedman J
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23704424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When a Parkinson's disease patient starts to hallucinate.
    Poewe W
    Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotic symptoms in Parkinson’s disease.
    Henrichsmann M
    Med Monatsschr Pharm; 2016 Jul; 39(7):293-5. PubMed ID: 29953182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dyskinesia-hyperpyrexia syndrome in a patient with Parkinson's disease: a case report].
    Taguchi S; Niwa J; Ibi T; Doyu M
    Rinsho Shinkeigaku; 2015; 55(3):182-4. PubMed ID: 25786757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.